Compare Kroger Co (KR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs State Street SPDR S&P Biotech ETF — how do they compare? Kroger Co trades at $55.74 (market cap $34.46B), while State Street SPDR S&P Biotech ETF trades at $159.27. The key difference: Kroger Co pays a 2.56% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kroger Co nearer its low. Which is the better fit depends on your goals.
| KR | XBI | |
|---|---|---|
Market Cap | $34.46B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $75.60 | $164.28 |
52-Week Low | $55.53 | $86.92 |
Enterprise Value | $54.56B | — |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.48, down 0.44% on the day, with a bearish technical signal driven by moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates by $0.01, but maintains a strong cash flow position with $2.08B net cash flow in 2025. Recent corporate actions include dividend payments, and news highlights e-commerce leadership changes and product recalls.
The outlook is balanced; analyst consensus is a Buy with a $68.25 price target, implying 21% upside, supported by stable revenue and margin expansion. Risks include competitive pressures, debt increase, and operational challenges from recent recalls. The stock offers value with a low P/S ratio but faces near-term technical headwinds.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
